A phase I clinical trial was conducted to evaluate a monovalent influenza DNA vaccine containing the HA gene from A/Panama/2007/99 delivered by particle-mediated epidermal delivery (PMED). Three groups of 12 healthy adult subjects received a single dose on day 0 of either 1, 2 or 4 microg of DNA vaccine, delivered as 1, 2 or 4 PMED administrations. The PMED influenza DNA vaccine elicited serum hemagglutination-inhibition (HAI) antibody responses at all three dose levels, with the highest and most consistent responses in subjects vaccinated with the highest dose level. Antibody responses were greatest at the last time point tested, day 56. Treatment-related reactions were mild to moderate, and included skin reactions at the vaccine site. These results provide a preliminary indication of the safety and immunogenicity of a prototype epidermal DNA vaccine for influenza.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2005.08.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immune evasion through mitochondrial transfer in the tumour microenvironment.
Nature
January 2025
Division of Cell Therapy, Chiba Cancer Center Research Institute, Chiba, Japan.
Cancer cells in the tumour microenvironment use various mechanisms to evade the immune system, particularly T cell attack. For example, metabolic reprogramming in the tumour microenvironment and mitochondrial dysfunction in tumour-infiltrating lymphocytes (TILs) impair antitumour immune responses. However, detailed mechanisms of such processes remain unclear.
View Article and Find Full Text PDFTroTNFα, a teleost tumour necrosis factor of golden pompano (Trachinotus ovatus), enhances pathogen clearance and acts as an immune adjuvant.
Int J Biol Macromol
January 2025
Sanya Institute of Breeding and Multiplication, School of Marine Biology and Fisheries, Collaborative Innovation Center of Marine Science and Technology, Hainan University, China; Engineering Research Center of Hainan Province for Blue Carbonand Coastal Wetland Conservation and Restoration, China; International Joint Research Center of Hainan Province for Blue Carbon and Coastal Wetland, China. Electronic address:
Tumour necrosis factor (TNF) is one of the most pivotal factors of the TNF family and plays an essential biological role in immunity. However, the antibacterial function and mechanism of TNFα in teleosts are relatively poorly understood. In this study, a novel TNFα from Trachinotus ovatus (TroTNFα) was characterized.
View Article and Find Full Text PDFDNA Nanostructures-Based In Situ Cancer Vaccines: Mechanisms and Applications.
Small Methods
January 2025
Department of Pharmaceutics, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, 410013, P. R. China.
Current tumor vaccines suffer from inadequate immune responsive due to the insufficient release of tumor antigens, low tumor infiltration, and immunosuppressive microenvironment. DNA nanostructures with their ability to precisely engineer, controlled release, biocompatibility, and the capability to augment the immunogenicity of tumor microenvironment, have gained significant attention for their potential to revolutionize vaccine designing. This review summarizes various applications of DNA nanostructures in the construction of in situ cancer vaccines, which can generate tumor-associated antigens directly from damaged tumors for cancer immune-stimulation.
View Article and Find Full Text PDFDevelopment of nucleic acid-based vaccines against dengue and other mosquito-borne flaviviruses: the past, present, and future.
Front Immunol
January 2025
Infectious Disease Research Department, King Abdullah International Medical Research Center, King Saud bin Abdulaziz University of Health Sciences, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.
Due to their widespread geographic distribution and frequent outbreaks, mosquito-borne flaviviruses, such as DENV (DENV), Zika virus (ZIKV), Japanese encephalitis virus (JEV), yellow fever virus (YFV), and West Nile virus (WNV), are considered significant global public health threats and contribute to dramatic socioeconomic imbalances worldwide. The global prevalence of these viruses is largely driven by extensive international travels and ecological disruptions that create favorable conditions for the breeding of and species, the mosquito vectors responsible for the spread of these pathogens. Currently, vaccines are available for only DENV, YFV, and JEV, but these face several challenges, including safety concerns, lengthy production processes, and logistical difficulties in distribution, especially in resource-limited regions, highlighting the urgent need for innovative vaccine approaches.
View Article and Find Full Text PDFAssessment of heat-killed expressing Chikungunya virus E2 protein as a candidate vaccine for dual protection against Chikungunya virus and .
Front Immunol
January 2025
Nanobioscience Group, Agharkar Research Institute, Pune, India.
The Chikungunya virus (CHIKV) is a mosquito-borne virus with a long history of recurring epidemics transmitted through mosquitoes. The rapid spread of CHIKV has intensified the need for potent vaccines. Escherichia coli (), a vital part of human gut microbiota, is utilized in recombinant DNA technology for cloning.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!